Our Curious Amalgam

The episode provides solid, actionable insights for directors on antitrust oversight, particularly the 'nose in, fingers out' framework and specific questions to ask management. However, much of the content relies on general governance principles (compliance program testing, ownership clarity, documentation) that are standard across enterprise risk management. There are few truly novel insights beyond restating that antitrust has expanded beyond M&A - the specifics of how conduct risk differs from merger risk are underdeveloped.

“antitrust is a standing condition of how the company competes”

“A program that never catches anything is not an effective program. It's a sleeping program.”

The core framing - that boards should oversee antitrust as enterprise risk rather than legal mechanics - is sensible but not particularly fresh. The 'nose in, fingers out' concept is borrowed from elsewhere and applied straightforwardly. The analogy to scuba diving, while clever, is more metaphorical than substantive. The episode recycles familiar Delaware governance cases (Caremark, Marchand, Boeing) without extracting novel lessons specific to antitrust.

“Risk and opportunity are two sides of the same coin”

“antitrust is being handled episodically, not overseen”

Julie Goshorn is a highly credible guest with deep practitioner experience across DOJ, FTC, private practice (Arnold & Porter), and in-house (Visa). She has built compliance programs at scale and understands both legal and board-level perspectives on antitrust. Her background legitimizes her advice. However, she is introduced as a former practitioner now serving on boards, not a current C-suite operator or current government enforcer, which slightly limits her currency on emerging enforcement priorities.

“more than two decades advising companies and government agencies on some of the most complicated antitrust issues”

“senior managing counsel at Visa, where she built the company's global competition compliance program”

The episode includes a few concrete examples (Meta/Zuckerberg email, Paramount-Warner Bros. deal, Section 8 interlock cases) but treats them largely illustratively rather than analytically. Most discussion remains abstract: 'pricing, bidding, hiring' as risk areas; 'states have built antitrust muscle' without naming enforcement patterns; 'compliance programs should test' without detailing what testing looks like. The Delaware cases are named but not deeply analyzed. Actionable guidance (three questions for new directors) is stated but not grounded in specific failure modes.

“Take Meta. FTC did not challenge the Instagram deal when then Facebook at the time it bought it. However, Years later, the FTC built a monopolization case anchored by a 2008 Mark Zuckerberg email”

“a coalition of state attorneys general is trying to block the Paramount Warner Brothers deal even after DOJ decided not to challenge the deal”

The hosts ask competent, well-structured questions that follow up logically ('why does this gap matter now?', 'what changed over a decade?', 'what should new directors ask?'). However, they rarely push back, challenge claims, or probe deeper when Goshorn offers broad assertions. For instance, when she claims executives 'write the government's complaint,' this is illustrated with one example but not challenged on frequency or countercases. The conversation feels more like a well-organized interview than a substantive probe. There is minimal disagreement or tension that would test ideas.

“What questions would I ask?”

“But from the Board's perspective, how can you tell the difference between like a, uh, genuinely effective and like being updated and actually functioning compliance program”